| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 World Health Organization (WHO) Collaborating Centre for Tuberculosis and Lung Diseases, Dept of Pneumonology, S. Maugeri Foundation, Care and Research Institute, Tradate, 2 Supranational Reference Laboratory, Dept of Bacteriology and Medical Micology, Istituto Superiore di Sanità, Rome, 4 National Reference Laboratory, Villa Marelli Institute, Milan, 3 Tuberculosis Dept, E. Morelli Hospital, Sondalo, 5 Division of Respiratory Diseases, University Tor Vergata, L. Spallanzani Hospital, Rome, 6 Dept of Clinical Microbiology, General Hospital Umberto I-Torrette, Ancona and 7 Institute of Infectious Diseases, Sacco Hospital, University of Milano, Milan, Italy
CORRESPONDENCE: G.B. Migliori, WHO Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione Salvatore Maugeri, via Roncaccio, 16, 21049, Tradate (VA), Italy. Fax: 39 0331829402. E-mail: gbmigliori@fsm.it
Keywords: drug, immigrant, prevalence of resistance, proficiency testing, susceptibility testing, tuberculosis
Received: June 3, 2002
Accepted September 25, 2002
This study was supported by grants from Istituto Superiore di Sanità, Rome, (National Tuberculosis Project), from the WHO and from AIPO, Grant No. TBC1.
In 1998 a network of 20 regional tuberculosis (TB) laboratories (the Italian Multicentre Study on Resistance to Antituberculosis drugs (SMIRA) network) was established in Italy to implement proficiency testing and to monitor the prevalence of drug resistance nationwide. The network managed 30% of all TB cases reported in Italy each year.
The aim of the present report is to describe: 1) the accuracy of drug-susceptibility testing in the network; 2) the prevalence of drug resistance for the period 1998–2000.
Data were collected from the network laboratories. Sensitivity to streptomycin and ethambutol increased from the first survey (1998–1999) to the second survey (2000) from 87.7 to 91.9%. Specificity, predictive values for resistance and susceptibility, efficiency and reproducibility were consistent in both surveys. In previously untreated cases, the prevalence of multidrug-resistance was the same in both surveys (1.2%), while a slight decrease from the first to the second survey was observed for monoresistance to rifampicin (from 0.8 to 0.4%) and isoniazid (from 2.9 to 2%).
The significant association found between isoniazid resistance and immigration is a useful indicator for both clinicians managing individual tuberculosis cases and public health services planning control strategies.
This article has been cited by other articles:
|
|
 |
|
  P. Miotto, F. Piana, V. Penati, F. Canducci, G. B. Migliori, and D. M. Cirillo Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Clinical Strains Isolated in Italy. J. Clin. Microbiol., July 1, 2006; 44(7): 2485 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Faustini, A J Hall, and C A Perucci Risk factors for multidrug resistant tuberculosis in Europe: a systematic review Thorax, February 1, 2006; 61(2): 158 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cazzadori, B. Allegranzi, A. Scardigli, F. Favari, and E. Concia Is the Recommendation Not To Use Rifampin Plus Pyrazinamide for Latent Tuberculosis Treatment Always Imperative? Chest, August 1, 2004; 126(2): 657 - 658. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
